Clinical trialNCT03910244CompletedPhase 2Interventional

Pomalidomide for the Treatment of Bleeding in HHT

SponsorThe Cleveland ClinicEnrollment145Telangiectasia, Hereditary Hemorrhagic

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks. Mean change from baseline to 24 weeks in the Epistaxis Severity Score (ESS) will be compared between treatment groups to determine pomalidomide efficacy.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

Keith McCrae, MD
The Cleveland Clinic
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Alabama at Birmingham
Birmingham, Alabama, United States
Ucsd Hemophilia and Thrombosis Treatment Center
San Diego, California, United States
Ucsf Outpatient Hematology Clinic
San Francisco, California, United States
University of Florida
Gainesville, Florida, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Massachussets General Hospital
Boston, Massachusetts, United States
University of Minnesota Health Clinical Research Unit
Minneapolis, Minnesota, United States
Mayo Clinic
Rochester, Minnesota, United States
University of North Carolina
Chapel Hill, North Carolina, United States
Cleveland Clinic
Cleveland, Ohio, United States
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania, United States
Baylor College of Medicine, Texas Children'S Hospital
Houston, Texas, United States
University of Utah Healthcare
Salt Lake City, Utah, United States
Medical College of Wiconsin
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

PlaceboPomalidomide →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 17 Oct 2019
Primary completion: 8 Sept 2023
Completion: 8 Sept 2023
Last update posted: 23 Oct 2024
Registered enrollment: 145
Registry id: NCT03910244

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.